This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This is why not many Pharmacompanies specifically specialize in discovering and developing pediatric cancer treatments; a great example of advancing new therapies for childhood cancer is the biotech Oncoheroes. This treatment was developed by performing a chemical screening on zebrafish.
Not really, although I contemplated medicalschool for a while. But then I dated a medical student in my first year of university and soon realized I did not think I could handle an entire class of people like him for four to eight years (no offense to MDs everywhere!).
He subsequently was accepted at Harvard MedicalSchool in Boston, USA, where he received his Ph.D. Furthermore, Evotec developed innovative partnership models with academia, biotech and pharmacompanies to accelerate the translation of academic discoveries into promising co-owned product opportunities.
First, most are on the payroll of the big pharmacompanies earning lucrative commissions for pushing their drugs…. By offering you another natural option, they are going against everything they have been taught during and since medicalschool and much of what the medical industry stands for….
Yang pointed out that “the fact that it’s generic is a double-edged sword, because no big pharmacompany is willing to invest a lot of money in developing and marketing a polypill. It may require either health insurance companies or governments or charitable organizations to develop polypills.”
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content